We are a multidisciplinary team at the Department of Oncology–Pathology, Karolinska Institutet, bringing together clinicians, molecular biologists, bioinformaticians, epidemiologists, biostatisticians, and AI engineers. We combine clinical research with profiling of tumor tissue and blood to understand treatment resistance and identify predictive biomarkers.
Our goal is to advance precision oncology by developing and validating biomarkers that can guide treatment choices and improve patient outcomes.
Based at Bioclinicum (Solna), Stockholm, we collaborate widely across KI and with partners in Europe, the US and beyond.
7 April 2026
Rong and Konstantinos have been awarded a Blue Sky Grant! Congratulations to Dr. Rong Deng and Dr. Konstantinos Georgiadis, postdocs in our group, for being awarded a Blue Sky Grant each. This grant funds projects led by pairs of postdoctoral researchers and/or PhD students from different research groups within the Oncology-Pathology department at KI, for which they will receive SEK 300,000. Read more here.
17 March 2026
Ioannis and Andri receive research funding from Cancerfonden! We are happy and proud to announce that Assoc. Prof. Ioannis Zerdes has received the prestigious Junior Clinical Investigator Award from the Swedish Cancer Society (Cancerfonden). With this, he has been awarded six years of dedicated research time, besides his clinical work. Dr. Andri Papakonstantinou has also received funding from Cancerfonden in the form of Research Months, which includes 3 months of dedicated research time for three years. You can read more here.
23 January 2026
Kang finishes his PhD! Huge congratulations to Dr. Wang, who has done an amazing job these past years and defended his doctoral thesis on January 23, 2026. His oponent was renowned breast cancer researcher Professor Charles M. Perou from the University of North Carolina at Chapel Hill (USA). His dissertation was titled ‘Delineating the molecular landscape of breast cancer and response to neoadjuvant systemic treatment’, you can read more here. 
